Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients
The purpose of this study is to compare the performance of the Baska mask supraglottic airway device with a single use laryngeal mask device (LMA) in low-risk female patients.
The investigators have performed a number of studies on novel airway devices, including 3 studies on the Baska mask. This trial will compare some performance characteristics of the studied devices, including airway seal pressures, insertion success rates, device use difficulty scores. Additional performance and device safety data will be accumulated.
The investigators have two primary hypotheses, namely 1.Non-inferiority of first placement attempt success rate of the Baska mask vs LMA; and 2.greater seal pressure of the Baska mask vs LMA.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Supraglottic airway devices have established place in the airway management in patients undergoing general anesthesia.
The Baska mask is a new supraglottic airway device. It's features include:
- Non pressurized cuff designed to reduce the risk of oropharyngeal tissue damage.
- Improved cuff seal during the inspiratory phase of positive pressure ventilation
- An improved system for drainage of oropharyngeal contents intended to reduce the rate of lung aspiration.
- Integrated bite-block to reduce the risk of patients biting and blocking the airway.
This study is randomized, single-blinded, controlled trial. The participants will be allocated to two groups, in which either the Baska mask or the single use LMA will be the primary airway management device.
Clinical Research Ethics Committee approval has been obtained. Suitable participants will be recruited after written informed consent.
Standard anesthetic preassesment and anesthesia will be provided.
Consenting patients will be randomly allocated to either of the 2 study groups.
Protocol for airway size selection and attempts at placement will be followed.
The investigators will monitor a number of parameters, including time and ease of insertion, airway seal pressure, airway leak, complications related to device use and other.
Follow up will be performed.
The investigators have two primary hypotheses:
- That the Baska mask is non-inferior to LMA in respect if first placement attempt success rate. A greater than 15% difference in success rate will be considered a clinically important difference and will disprove this hypothesis.
- The Baska mask is superior in respect of seal pressure. A 20% higher seal pressure with Baska as compared to the LMA device seal pressure will be considered a clinically important difference.
Interim analysis will be performed once 75 patients are recruited per group. This is reasonable as this figure exceeds that required to prove or disprove the primary hypothesis regarding the seal pressure. The study will only be stopped at this stage if the non-inferiority hypothesis is disproven with P value < 0.01
In addition to the above the investigators will evaluate a number of secondary outcomes.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Galway, Irlanda
- Galway University Hospitals
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female
- Written informed consent
- ASA 1-3
- No relevant allergies
- Body-mass index (BMI) 35 or less
- Age 16-85
- Non-urgent surgery of planned duration under 4 hours
Exclusion Criteria:
- Inability of patient/parent to understand or consent for the trial
- Neck pathology
- Previous or anticipated problems with the upper airway or upper GI tract
- BMI >35
- Predicted or previously documented difficult airway
- Live Pregnancy
- Increased risk for Gastric Aspiration
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Baska mask
In this arm the Baska mask will be used as the airway management device
|
|
|
Comparador Ativo: single use laryngeal mask airway device (LMA)
in this arm a single use LMA device will be used for airway management.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of successful placement of the supraglottic device on first attempt
Prazo: within 30 minutes of commencement of general anesthesia
|
The hypothesis is that the Baska mask will have first time placement attempt success rate that is no more than 15% less than that of the comparator - a single use LMA device.
|
within 30 minutes of commencement of general anesthesia
|
|
Seal pressure of the supraglottic device
Prazo: Within 30 minutes of commencement of general anesthesia
|
The investigators will measure the airway seal provided by the device used.
The hypothesis is that the seal pressure of the Baska mask is 20% higher than that of the comparator single-use LMA device.
|
Within 30 minutes of commencement of general anesthesia
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall rate of successful placement of the supraglottic device
Prazo: Within 30 minutes of commencement of general anesthesia. Up to 3 device placement attempts are allowed.
|
Within 30 minutes of commencement of general anesthesia. Up to 3 device placement attempts are allowed.
|
|
|
Number of device placement attempts
Prazo: Within 30 minutes of commencement of general anesthesia
|
Within 30 minutes of commencement of general anesthesia
|
|
|
Number of optimization maneuvers during device placement
Prazo: Within 30 minutes of commencement of general anesthesia
|
Within 30 minutes of commencement of general anesthesia
|
|
|
user rated Device difficulty score
Prazo: within 30 minutes of commencement of general anesthesia
|
the investigators will use 10 cm visual analogue scale to score the whole experience of using the device until successful ventilation is achieved.
|
within 30 minutes of commencement of general anesthesia
|
|
vitals parameter stability
Prazo: in the period immediately before and within the first 35 minutes of general anesthesia
|
The investigators will record non-invasive arterial oxygen saturation, heart rate and blood pressure preoperatively, after induction of general anesthesia and after placement of the airway device.
|
in the period immediately before and within the first 35 minutes of general anesthesia
|
|
Laryngeal view obtained on fiberoptic assessment
Prazo: within 2 hours of commencement of general anesthesia
|
The investigators will perform this when feasible.
|
within 2 hours of commencement of general anesthesia
|
|
Complication rates
Prazo: from the moment general anesthesia commenced up to 3 days postoperatively
|
Complications specifically monitored will be: blood staining, laryngospasm, lip damage, throat pain, dysphagia, dysphonia, heartburn, nausea and vomiting. The investigators will record other complications related to the use of the device, including but not limited to: desaturation, need to reposition device or switch to alternative device, teeth damage, regurgitation, aspiration |
from the moment general anesthesia commenced up to 3 days postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Patrick Neligan, FFARCSI, Galway University Hospitals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- C.A.724
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .